Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers according to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil)

Trial Profile

A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers according to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Nov 2018

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top